A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. (Q42759889)
Jump to navigation
Jump to search
scientific article published on December 2010
Language | Label | Description | Also known as |
---|---|---|---|
English | A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. |
scientific article published on December 2010 |
Statements
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326 (English)
Grace K Dy
Alex A Adjei
Julian R Molina
Shauna L Hillman
Kendrith M Rowland
Preston D Steen
Donald B Wender
Sumithra Mandrekar
North Central Cancer Treatment Group Study N0326
1 December 2010
1 reference
1 reference